Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying vaccine therapy given after standard therapy to see how well it works in treating patients with stage III non-small cell lung cancer.

Key facts

Study ID

NCT00019929

Run by

National Cancer Institute (NCI)

Starts

2000-08-01

Expected to finish

2005-12-01

Last updated by the study team

2013-06-20

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.